Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

XmAb5485

Catalog No. T9901A-1755 Copy Product Info
🥰Excellent
XmAb5485 is a humanized anti-CD40 monoclonal antibody engineered with an Fc domain modification, exhibiting high affinity for Fc-γ receptors. It effectively induces antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) against tumor cells. Additionally, XmAb5485 suppresses tumor cell proliferation and triggers apoptosis. This compound demonstrates pronounced cytotoxicity against lymphoma, leukemia, multiple myeloma cell lines, and primary cancer cells.

XmAb5485

Copy Product Info
🥰Excellent
Catalog No. T9901A-1755

XmAb5485 is a humanized anti-CD40 monoclonal antibody engineered with an Fc domain modification, exhibiting high affinity for Fc-γ receptors. It effectively induces antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) against tumor cells. Additionally, XmAb5485 suppresses tumor cell proliferation and triggers apoptosis. This compound demonstrates pronounced cytotoxicity against lymphoma, leukemia, multiple myeloma cell lines, and primary cancer cells.

XmAb5485
Pack SizePriceUSA StockGlobal StockQuantity
1 mgInquiryInquiryInquiry
5 mgInquiryInquiryInquiry
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Questions
TargetMol
View More

Product Introduction

Bioactivity
Description
XmAb5485 is a humanized anti-CD40 monoclonal antibody engineered with an Fc domain modification, exhibiting high affinity for Fc-γ receptors. It effectively induces antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) against tumor cells. Additionally, XmAb5485 suppresses tumor cell proliferation and triggers apoptosis. This compound demonstrates pronounced cytotoxicity against lymphoma, leukemia, multiple myeloma cell lines, and primary cancer cells.
In vitro
XmAb5485 exhibits significant antibody-dependent cellular phagocytosis (ADCP) in Ramos cells. Additionally, it suppresses the proliferation and induces apoptosis of various primary patient-derived CLL, MCL cells, and plasma cell leukemia cells through antibody-dependent cell-mediated cytotoxicity (ADCC).
In vivo
XmAb5485 (6 mg/kg) successfully cured 80% of mice with detectable tumors and demonstrated significant antitumor activity in a mouse model with established large-volume (210-350 mm³) subcutaneous Ramos xenograft tumors.
Chemical Properties
Storage & Solubility Information
Storagestore at low temperature | store at -20°C | Shipping with blue ice/Shipping at ambient temperature.

Calculator

  • Dilution Calculator
  • Reconstitution Calculator
Related Tags: buy XmAb5485 | purchase XmAb5485 | XmAb5485 cost | order XmAb5485 | XmAb5485 in vivo | XmAb5485 in vitro